Figures & data
Table 1. Influence of the mass ratio of solid lipid materials to liquid lipid materials on the properties of DA-NLCs (Mean ± S.D., n = 3).
Table 2. Average particle size, polydispersity index and zeta potential of blank NLCs and DA-NLCs (mean±S.D., n = 3).
Figure 1. Transmission electron micrograph of DA-NLCs.
Figure 2. DSC Analysis: DSC thermograms of F68 (A), Compritol 888 ATO (B), DA-NLCs (C), blank NLCs (D), the physical mixture of DA and blank NLCs (E) and DA (F).(a, 55.6 °C; b, 75.1 °C; c, 54.3 °C d, 72.9 °C; e, 54.1 °C; f, 72.5 °C; g, 54.3 °C; h,72.9 °C; i, 235.1 °C).
Figure 3. The release profiles of DA from free DA and DXM-NLCs in pH7.4 PBS. Each point represents the mean ± S.D. (n = 3).
Figure 4. Concentration of DA in the pleural exudate after the intravenous administration of free DA and DA-NLCs to rats with experimental pleuritis (dose, 3 mg/kg). Each point represents the mean ± S.D. of 5 rats for each group.
Figure 5. The mean volume (ml) of γ-carrageenan-induced paw edema in Wistar rats. Values represent the mean ± S.D. of 5 animals for each group. Each value in parenthesis indicates the percentage inhibition rate.
Table 3. Major pharmacokinetic parameters of free DA and DXM-NLCs in plasma and tissues.
Figure 6. The DA concentrations in plasma, liver and lung (A) and other tissues (B) after intravenous administration of free DA and DA-NLCs.
